newsfilter
← Latest News
GlobeNewswire·

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring